||We built our Heart and Vascular Institute on the expertise of dozens of board-certified cardiologists and surgeons. Please use the directory below to find a doctor affiliated with the Heart and Vascular Institute, or call us anytime at 201-447-8456.
||From atrial fibrillation to Wolff-Parkinson-White syndrome and every diagnosis in between, we will care for you like no other hospital. It´s the advanced cardiac care you need – when and where you need it most. Please click below for an overview of the conditions we treat. If you would prefer to speak with us, please call 201-447-8456.
View an A – Z listing of the conditions we treat
|We treat virtually every type of cardiac and vascular diagnosis. Our network of board-certified cardiologists and surgeons is dedicated to providing you with the highest level of specialized care. Please click below for an overview of the treatments and procedures we provide. If you would prefer to speak with us, please call 201-447-8456.
View an A – Z listing of the treatments and procedures we perform
Support the Heart & Vascular Institute
|To learn more about how you can support our Heart & Vascular Institute, please contact The Valley Hospital Foundation at 201-291-6300. Philanthropy plays a vital role in funding our cutting-edge research and innovative patient care programs, as well as maintaining our state-of-the-art facilities.
You may also donate online by clicking here.
The purpose of this study is the Assessment of Clinical Effects of Cholerstyl Ester
Transfer Protein Inhibition with Evacetrapid in Patients at a High-Risk for Vascular
The purpose of this study is a randomized, double-blind, placebo-controlled, event-driven
trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular
events among stable post-myocardial infarction patients with elevated hsCRP.
The purpose of this study is A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group
Study to Evaluate the Effect of SAR236553/REGN727 on the Occurrence of Cardiovascular
Events in Patients Who Have Recently Experienced an Acute Coronary Syndrome.
The purpose of this study is a Vest prevention of Early Sudden Death Trial PREDiction
of ICD Treatment Study.
The purpose of this study is a Clinical Evaluation of the Absorb™ Bioresorbable
Vascular Scaffold (BVS) in the Treatment of Subjects with de novo Native Coronary
The purpose of this study is the Evaluation of XIENCE PRIME™ or XIENCE V® versus
Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization.
- Glagov (Amgen)
A Randomized, Multi-Center, Placebo-Controlled, Parallel Group Study to Determine
the Effects of AMG 145 Treatment on Atherosclerotic Disease Burden
An Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment
Strategies of rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment
Post-Approval Study Protocol of the St. Jude Medical Biocor™ and Biocor™ Supra Valve
Collection of Blood, Urine, and Tissue Specimens to Study Cardiovascular Disease
- Cardiac Surgery Tissue Banking
The purpose of this research is to obtain some of the excess tissue that is left
over from surgeries for future research. We also will collect two 10ml vials of
blood for use in future research.
Mechanical Strength Testing of Aortic Aneurysm Tissue The purpose of this study
is to test the strength of aneurysm tissue after it has been replaced during surgery.
- Secret CHF
A Randomized, Double-Blind, Placebo controlled Study of the Short Term Clinical
Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure with Challenging
This study is to learn if IDENTIFY-HF Risk Status Algorithm that uses information
from the Reveal® insertable cardiac monitor calculates a heart failure risk status
is able to predict the risk of a patient for going to the hospital for their heart
The purpose of this clinical study is to test the safety and effectiveness of the
Medtronic Attain Performa quadripolar, left ventricular pacing lead.
- REVEAL AF
To determine, via continuous monitoring with the Reveal XT implantable cardiac monitor
(ICM) or newer approved version (referred to as Reveal ICM), the incidence of atrial
fibrillation (AF) in patients suspected to be at high risk for having AF and to
understand how physicians manage these patients once AF has been detected.
- RESPOND CRT
The aim of this study is to evaluate the safety of the PARADYM RF SonR CRT-D device
and SonRtip lead. Furthermore, to evaluate the effectiveness of the SonR optimization
feature built into the device as compared to optimizing with echocardiography, which
is the current clinical practice.
To see how effective a drug called ranolazine is in reducing the risk of fast cardiac
arrhythmias and death in people with ICDs.
To evaluate the safety of Rivaroxaban and uninterrupted Vitamin K Antagonists (VKA)
in adult subjects with NonValvular Atrial Fibrillation (NVAF) who undergo catheter
ablation as measured by post-procedure major bleeding events.
The CABANA trial is designed to test whether the treatment strategy of left atrial
catheter ablation for the purpose of eliminating atrial fibrillation (AF) will be
superior to current rate control or rhythm control drugs for reducing total mortality
in patients with untreated or incompletely treated AF.
The purpose of this study is a Global Registry on Long-Term Oral Anti-thrombotic
Treatment in Patients with Atrial Fibrillation (Phase II/III)
The purpose of this study is an International Study of Comparative Health Effectiveness
with Medical and Invasive Approaches.
- Penumbra 3D
The purpose of this study is a randomized, concurrent controlled trial to assess
the safety and effectiveness of the Separator 3D as a component of the Penumbra
System in the revascularization of large vessel occlusion in acute ischemic stroke
The purpose of this study is The Randomized, Concurrent Controlled Trial to Assess
the Penumbra System's Safety and Effectiveness in the Treatment of Acute Stroke
The purpose of this study is An Aneurysm Coiling Efficiency Study of the Penumbra
Coil 400 System.
Valley Specialized Services